Get the Stockscreener App
1.16
4.92%
-0.06
Pre-market:
1.18
0.02
+1.72%
Outlook Therapeutics Inc stock is traded at $1.16, with a volume of 23.20M.
It is down -4.92% in the last 24 hours and up +408.55% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.22
Open:
$1.32
24h Volume:
23.20M
Relative Volume:
1.47
Market Cap:
$172.36M
Revenue:
$424.90K
Net Income/Loss:
$-94.02M
P/E Ratio:
-0.467
EPS:
-2.4842
Net Cash Flow:
$-51.25M
1W Performance:
+60.66%
1M Performance:
+408.55%
6M Performance:
-46.54%
1Y Performance:
-36.26%
1-Day Range:
$1.13
$1.40
1-Week Range:
$0.6752
$1.40
52-Week Range:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.16 | 172.36M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD - Yahoo Finance Singapore
Outlook Therapeutics Surges As FDA Fast-Tracks ONS-5010 Review - timothysykes.com
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission - Yahoo Finance Singapore
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
OTLK Jumps As Outlook Therapeutics Wins FDA Backing On BLA Resubmission - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Review - timothysykes.com
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Resubmission - StocksToTrade
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Decision - timothysykes.com
Why Is OTLK Stock Falling Today? - Stocktwits
📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈 - Moomoo
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.00 - GuruFocus
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up - TechStock²
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
Outlook Therapeutics gains on FDA appeal win, boosting chances for Lytenava approval. - Pluang
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares - Investing.com UK
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock Forum and Discussion - Moomoo
Director at Outlook Therapeutics (NASDAQ: OTLK) buys 29,000 shares - Stock Titan
OTLK stock surges on FDA Lytenava application resubmission after successful appeal - MSN
Outlook Therapeutics Resubmits FDA Application for ONS-5010 - The Globe and Mail
$Outlook Therapeutics (OTLK.US)$ Looking forward to seeing what you can do tonight. - Moomoo
Outlook Therapeutics director’s firm buys $5m in common stock - Investing.com UK
Outlook Therapeutics director’s firm buys $5m in common stock By Investing.com - Investing.com South Africa
GMS Ventures lifts Outlook Therapeutics (OTLK) stake in $5M share deal - Stock Titan
[SCHEDULE 13D/A] Outlook Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Outlook Therapeutics resubmits drug application to FDA - Investing.com UK
Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win - Eyes On Eyecare
Outlook Therapeutics (NASDAQ: OTLK) seeks approval for reverse split and major share increase - Stock Titan
Outlook Therapeutics resubmits drug application to FDA By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Resubmits Biologics License Applicat - GuruFocus
Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA? (bevacizumab-vikg) - marketscreener.com
Outlook Therapeutics (Nasdaq: OTLK) resubmits FDA BLA with 60-day review - Stock Titan
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - The Manila Times
U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics - Traders Union
Outlook Therapeutics Announces Resubmission of Biologics - GlobeNewswire
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):